BioPorto Diagnostics

Acute Kidney Injury (AKI) adversely impacts 25% of critically ill children and can be hard to identify with serum creatinine alone. ProNephro AKI™ (NGAL) is the first FDA-cleared test for assessing AKI risk in ICU patients 3 months to 22 years. A low NGAL result indicates a low risk of AKI, allowing for confident use of interventions such as fluids, diuretics, or nephrotoxic medications. Elevated NGAL values signal a high risk of developing AKI, triggering nephrology consults and interventions 2-3 days before serum creatinine rises.

Visit BioPorto Diagnostics at booth 839 to learn how ProNephro AKI can improve AKI detection and management in your patients. Plus, get an update on our adult clinical trial.